<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">vZJjH3CvjdVjtXJcCHQHJRn</article-id>
      <article-id pub-id-type="other">00016</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000100016</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400116</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000100016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anemia e insufici&#234;ncia card&#237;aca na comunidade: compara&#231;&#227;o com um ambulat&#243;rio especializado</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Eduarda Barcellos dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tello</surname>
            <given-names>Bol&#237;var Saenz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Villacorta</surname>
            <given-names>Humberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sales</surname>
            <given-names>Ana Luisa Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wiefels</surname>
            <given-names>Christiane</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teixeira</surname>
            <given-names>Pedro Soares</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima Filho</surname>
            <given-names>Luis Costa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Evandro Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Niter&#243;i</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal Fluminense</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>1</issue>
      <fpage>102</fpage>
      <lpage>108</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>12</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>07</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>05</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A anemia &#233; comum em pacientes com insufici&#234;ncia card&#237;aca (IC). Sua preval&#234;ncia em pacientes com IC na comunidade &#233; desconhecida em nosso meio. OBJETIVO: Avaliar a preval&#234;ncia e caracter&#237;sticas de pacientes com anemia em uma popula&#231;&#227;o n&#227;o selecionada com IC na comunidade, comparando-a a uma popula&#231;&#227;o com IC atendida em um ambulat&#243;rio especializado. M&#201;TODOS: Estudo transversal, prospectivo, observacional, realizado de janeiro de 2006 a mar&#231;o de 2007. Os pacientes com IC preenchiam os crit&#233;rios de Boston, com pontua&#231;&#227;o &gt;8. Anemia foi definida pelos crit&#233;rios da Organiza&#231;&#227;o Mundial de Sa&#250;de, como valores de hemoglobina &lt;13 g/dl para homens e &lt;12 g/dl para mulheres. Foram selecionados aleatoriamente pacientes atendidos em um programa de aten&#231;&#227;o prim&#225;ria na comunidade e pacientes atendidos em um ambulat&#243;rio de insufici&#234;ncia card&#237;aca em um hospital universit&#225;rio. RESULTADOS: Avaliados 206 pacientes com m&#233;dia de idade de 61,3&#177;13,1 anos, 53,4% do sexo feminino. A preval&#234;ncia da anemia na comunidade (n=114) foi de 21% e no ambulat&#243;rio (n=92), de 25% (p=0,50). Os pacientes da comunidade apresentavam menor taxa de disfun&#231;&#227;o renal (TFG&lt;60 ml/min/1,73-5), predomin&#226;ncia de IC com fra&#231;&#227;o de eje&#231;&#227;o normal e sexo feminino. Par&#226;metros de fun&#231;&#227;o renal (ur&#233;ia ou cretinina) relacionaram-se de modo independente com a anemia, nas duas popula&#231;&#245;es. CONCLUS&#195;O: A preval&#234;ncia da anemia foi semelhante nas popula&#231;&#245;es estudadas. A fun&#231;&#227;o renal foi o &#250;nico fator relacionado de modo independente com a anemia nas duas popula&#231;&#245;es.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Anemia</kwd>
        <kwd>preval&#234;ncia</kwd>
        <kwd>insufici&#234;ncia card&#237;aca</kwd>
        <kwd>estudo comparativo</kwd>
        <kwd>ambulat&#243;rio hospitalar</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> INSUFICI&#202;NCIA CARD&#205;ACA</p>
    <p>
      <bold>Anemia e insufici&#234;ncia card&#237;aca na comunidade: compara&#231;&#227;o com um ambulat&#243;rio especializado</bold>
    </p>
    <p>
      <bold>Eduarda Barcellos dos Santos; Bol&#237;var Saenz Tello; Humberto Villacorta; Ana Luisa Ferreira Sales; Christiane Wiefels; Pedro Soares Teixeira; Luis Costa Lima Filho; Evandro Tinoco Mesquita</bold>
    </p>
    <p>Universidade Federal Fluminense, Niter&#243;i, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> A anemia &#233; comum em pacientes com insufici&#234;ncia card&#237;aca (IC). Sua preval&#234;ncia em pacientes com IC na comunidade &#233; desconhecida em nosso meio. </p>
    <p><bold>OBJETIVO: </bold> Avaliar a preval&#234;ncia e caracter&#237;sticas de pacientes com anemia em uma popula&#231;&#227;o n&#227;o selecionada com IC na comunidade, comparando-a a uma popula&#231;&#227;o com IC atendida em um ambulat&#243;rio especializado. </p>
    <p><bold>M&#201;TODOS: </bold> Estudo transversal, prospectivo, observacional, realizado de janeiro de 2006 a mar&#231;o de 2007. Os pacientes com IC preenchiam os crit&#233;rios de Boston, com pontua&#231;&#227;o <underline>&gt;</underline>8. Anemia foi definida pelos crit&#233;rios da Organiza&#231;&#227;o Mundial de Sa&#250;de, como valores de hemoglobina &lt;13 g/dl para homens e &lt;12 g/dl para mulheres. Foram selecionados aleatoriamente pacientes atendidos em um programa de aten&#231;&#227;o prim&#225;ria na comunidade e pacientes atendidos em um ambulat&#243;rio de insufici&#234;ncia card&#237;aca em um hospital universit&#225;rio. </p>
    <p><bold>RESULTADOS: </bold> Avaliados 206 pacientes com m&#233;dia de idade de 61,3&#177;13,1 anos, 53,4% do sexo feminino. A preval&#234;ncia da anemia na comunidade (n=114) foi de 21% e no ambulat&#243;rio (n=92), de 25% (p=0,50). Os pacientes da comunidade apresentavam menor taxa de disfun&#231;&#227;o renal (TFG&lt;60 ml/min/1,73<sup>-5</sup>), predomin&#226;ncia de IC com fra&#231;&#227;o de eje&#231;&#227;o normal e sexo feminino. Par&#226;metros de fun&#231;&#227;o renal (ur&#233;ia ou cretinina) relacionaram-se de modo independente com a anemia, nas duas popula&#231;&#245;es. </p>
    <p><bold>CONCLUS&#195;O: </bold> A preval&#234;ncia da anemia foi semelhante nas popula&#231;&#245;es estudadas. A fun&#231;&#227;o renal foi o &#250;nico fator relacionado de modo independente com a anemia nas duas popula&#231;&#245;es.</p>
    <p><bold>Palavras-chave: </bold> Anemia, preval&#234;ncia, insufici&#234;ncia card&#237;aca, estudo comparativo, ambulat&#243;rio hospitalar.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A Insufici&#234;ncia Card&#237;aca (IC) &#233; considerada um problema de sa&#250;de p&#250;blica nos Estados Unidos<sup>1</sup>. A doen&#231;a &#233; a principal raz&#227;o de visitas a consult&#243;rios m&#233;dicos e h&#225; um n&#250;mero cada vez maior de hospitaliza&#231;&#245;es<sup>2,3</sup>.</p>
    <p>No Brasil, a IC &#233; o terceiro motivo de interna&#231;&#227;o entre todas as causas e o primeiro entre as doen&#231;as cardiovasculares (DCV) no Sistema &#218;nico de Sa&#250;de (SUS), em pacientes acima de 65 anos, elevando os custos com essa doen&#231;a<sup>4,5</sup>. O impacto no sistema p&#250;blico brasileiro tamb&#233;m pode ser avaliado atrav&#233;s dos dados de um estudo, onde foram avaliadas interna&#231;&#245;es por IC em hospitais p&#250;blicos e privados em uma cidade brasileira no ano de 2001, mostrando que os pacientes atendidos em hospitais p&#250;blicos s&#227;o em m&#233;dia 10 anos mais jovens e apresentam maior tempo de interna&#231;&#227;o hospitalar que os da rede privada<sup>6</sup>.</p>
    <p>Estudos populacionais mostram que a IC tem alta preval&#234;ncia na comunidade, havendo predom&#237;nio de IC com fra&#231;&#227;o de eje&#231;&#227;o normal (ICFEN)<sup>7,8</sup>. Embora a ICFEN tenha sido vista como uma doen&#231;a de menor gravidade no passado, dados atuais mostram sua import&#226;ncia cl&#237;nica pelo incremento na mortalidade anual de 5% a 8% (comparado a 10% a 15% da IC com fra&#231;&#227;o de eje&#231;&#227;o reduzida)<sup>9</sup>.</p>
    <p>A anemia &#233; comum nos pacientes com IC e tem sido proposta como novo alvo terap&#234;utico nessa popula&#231;&#227;o. Silverberg e cols.<sup>10-12</sup> foram os primeiros a detalhar o papel da anemia na IC e introduziram o conceito de que a corre&#231;&#227;o da anemia poderia contribuir para melhora cl&#237;nica dos pacientes com IC<sup>10-12</sup>.</p>
    <p>Condi&#231;&#227;o comum nos pacientes com IC, particularmente nos idosos, a anemia tem preval&#234;ncia aumentada quanto maior a gravidade da doen&#231;a<sup>10-12</sup>. A preval&#234;ncia de anemia em pacientes com IC varia de 4% a 62% na literatura<sup>13-20</sup>. Resultados t&#227;o variados devem-se aos diferentes crit&#233;rios utilizados para o diagn&#243;stico de anemia e &#224;s diferentes popula&#231;&#245;es estudadas.</p>
    <p>Diversos estudos t&#234;m estabelecido que a presen&#231;a da anemia em pacientes com IC est&#225; associada a pior progn&#243;stico e a maior morbidade e mortalidade cardiovascular<sup>13-27</sup>.</p>
    <p>Em nosso meio h&#225; poucos estudos de anemia na comunidade. A vantagem desses estudos &#233; obter-se dados de popula&#231;&#245;es n&#227;o selecionadas, diferentemente de estudos em ambientes terci&#225;rios, onde pacientes mais graves s&#227;o atendidos. Em estudo nacional recente, confirmou-se que, em nosso meio, na comunidade h&#225; predom&#237;nio de ICFEN em rela&#231;&#227;o a IC com fra&#231;&#227;o de eje&#231;&#227;o reduzida (ICFER)<sup>28</sup>, o que difere do observado em servi&#231;os de refer&#234;ncia para IC.</p>
    <p>O objetivo deste trabalho foi determinar a preval&#234;ncia e as caracter&#237;sticas cl&#237;nicas de pacientes portadores de anemia em uma popula&#231;&#227;o com IC cr&#244;nica na comunidade, comparando-as a pacientes atendidos em um ambulat&#243;rio especializado em IC.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Este foi um estudo observacional, transversal, prospectivo, que envolveu pacientes com diagn&#243;stico de IC, pertencentes a um programa de m&#233;dico de fam&#237;lia (PMF) e pacientes de um ambulat&#243;rio especializado de um hospital universit&#225;rio (HU). Foram realizadas visitas aos postos de sa&#250;de do PMF, de diferentes bairros, para catalogar os casos suspeitos de IC, em indiv&#237;duos com idade acima de 18 anos identificados pelos m&#233;dicos generalistas. As informa&#231;&#245;es foram colhidas atrav&#233;s de question&#225;rios com dados de hist&#243;ria cl&#237;nica, dados demogr&#225;ficos, h&#225;bitos de vida, exame f&#237;sico, dados antropom&#233;tricos, quantifica&#231;&#227;o da classe funcional (CF) seguindo os crit&#233;rios da New York Heart Association (NYHA) e an&#225;lise dos exames complementares (eletrocardiograma, radiografia de t&#243;rax e ecodopplercardiograma) e medica&#231;&#245;es em uso. Os pacientes eram encaminhados ao ambulat&#243;rio de IC do HU, para complementa&#231;&#227;o de dados do question&#225;rio, que porventura n&#227;o pudessem ser obtidos no dia da visita ao posto de sa&#250;de.</p>
    <p>O ecodopplercardiograma foi realizado em todos os pacientes. Aqueles que n&#227;o dispunham do exame, foram submetidos a essa avalia&#231;&#227;o no servi&#231;o de ecocardiografia do HU. Mediu-se a fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) pelo m&#233;todo de Simpson e classificaram-se os pacientes em portadores de ICFER, quando apresentavam FEVE&lt;50% e portadores de ICFEN quando esta era <underline>&gt;</underline>50%.</p>
    <p>Os pacientes do HU, j&#225; possu&#237;am o diagn&#243;stico de IC, j&#225; fazendo uso de medica&#231;&#227;o adequada. Foram submetidos a novos exames laboratoriais e de imagem ao concordarem em fazer parte do estudo. Todos os pacientes com diagn&#243;stico de IC preenchiam os crit&#233;rios de Boston para IC com pontua&#231;&#227;o maior ou igual a 8. O per&#237;odo de inclus&#227;o do estudo foi de janeiro de 2006 a mar&#231;o de 2007. Foram exclu&#237;dos pacientes com doen&#231;a renal avan&#231;ada (terapia dial&#237;tica).</p>
    <p>Anemia foi definida pelos crit&#233;rios da Organiza&#231;&#227;o Mundial de Sa&#250;de (OMS) em que s&#227;o caracterizados como an&#234;micos homens com hemoglobina s&#233;rica &lt;13 g/dl e mulheres com valores &lt;12 g/dl. A fun&#231;&#227;o renal foi avaliada atrav&#233;s da ur&#233;ia e creatinina s&#233;ricas e pela taxa de filtra&#231;&#227;o glomerular (TFG) estimada, calculada pela f&#243;rmula sMDRD (<italic>Simplified Modified Diet Renal Disease</italic>). Esta f&#243;rmula tem sido validada em v&#225;rios estudos, em diferentes popula&#231;&#245;es e tem sido usada para estimar a TFG em pacientes com IC. Obesidade foi definida como a presen&#231;a de &#237;ndice de massa corp&#243;rea (IMC) &gt; 30 e desnutri&#231;&#227;o como IMC &lt; 17.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>As vari&#225;veis cont&#237;nuas foram expressas como m&#233;dias e seus respectivos desvios padr&#245;es e comparadas pelo teste t de Student. As vari&#225;veis categ&#243;ricas se expressaram sob forma de valores absolutos e percentagem e foram comparadas utilizando-se o teste de qui-quadrado ou teste exato de Fischer para as amostras com valores esperados menores que cinco. As vari&#225;veis com valor de p&lt;0,10 na an&#225;lise univariada foram inclu&#237;das na an&#225;lise multivariada (regress&#227;o log&#237;stica), com o objetivo de verificar quais apresentavam rela&#231;&#227;o independente com a presen&#231;a de anemia. A an&#225;lise foi realizada pelos programas estat&#237;sticos EPIINFO 3.4 e SPSS, vers&#227;o 11.0. Valores de p&lt;0,05 foram considerados estat&#237;sticamente significativos. O crit&#233;rio de determina&#231;&#227;o de signific&#226;ncia adotado foi o n&#237;vel de 5%.</p>
    <p>
      <bold>Bio&#233;tica</bold>
    </p>
    <p>O estudo foi aprovado pelo comit&#234; de &#233;tica em pesquisa de nosso hospital, estando de acordo com a Declara&#231;&#227;o de Helsinki, sendo obtido termo de consentimento livre e esclarecido de todos os participantes.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>O estudo envolveu 206 pacientes com diagn&#243;stico de IC, de 2 popula&#231;&#245;es distintas (ambulat&#243;rio especializado e da comunidade). A m&#233;dia de idade foi de 61,3&#177;13 anos, sendo 53,4% (110) do sexo feminino. A presen&#231;a de anemia foi observada em 47 (22,8%) dos 206 pacientes. Quando comparamos as preval&#234;ncias de anemia nas duas popula&#231;&#245;es, observamos que, apesar de a preval&#234;ncia ter sido discretamente superior no grupo HU (23 [25%] vs 24 [21%]), n&#227;o houve diferen&#231;a estatisticamente significativa (<xref ref-type="fig" rid="f1">Figura 1</xref>).</p>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gf01.jpg"/></fig>
    <p>A <xref ref-type="table" rid="t01">tabela 1</xref> mostra as caracter&#237;sticas cl&#237;nicas e demogr&#225;ficas das duas popula&#231;&#245;es. No grupo HU houve predom&#237;nio do sexo masculino, maior preval&#234;ncia de doen&#231;a arterial coronariana (DAC), pior fun&#231;&#227;o renal, pior fra&#231;&#227;o de eje&#231;&#227;o e apresenta&#231;&#227;o com menores valores de freq&#252;&#234;ncia card&#237;aca e press&#227;o arterial sist&#243;lica (PAS) e diast&#243;lica (PAD). No grupo PMF houve predom&#237;nio do sexo feminino, maior preval&#234;ncia de hipertens&#227;o arterial sist&#234;mica (HAS), dislipidemia e acidente vascular encef&#225;lico pr&#233;vio. No HU houve predom&#237;nio de disfun&#231;&#227;o sist&#243;lica de VE (54,3%), observando-se o oposto no grupo PMF, com preval&#234;ncia de 82,4% de ICFEN. Havia maior utiliza&#231;&#227;o de betabloqueadores, digoxina e diur&#233;ticos de al&#231;a no HU.</p>
    <p content-type="asset">
      <table-wrap id="t01">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt01.jpg"/></table-wrap>
    </p>
    <p>As <xref ref-type="table" rid="t02">tabelas 2</xref> e <xref ref-type="table" rid="t03">3</xref>, mostram as caracter&#237;sticas basais de pacientes an&#234;micos e n&#227;o an&#234;micos nas duas popula&#231;&#245;es, respectivamente. Observa-se que no grupo PMF, a anemia estava associada a menor PAS, presen&#231;a de edema perif&#233;rico, menores n&#237;veis de colesterol total, menor fra&#231;&#227;o de eje&#231;&#227;o, maiores valores de ur&#233;ia plasm&#225;tica e maior uso de digoxina e diur&#233;ticos de al&#231;a. No grupo HU, havia associa&#231;&#227;o com n&#237;veis de creatinina s&#233;rica e taxa de filtra&#231;&#227;o glomerular.</p>
    <p content-type="asset">
      <table-wrap id="t02">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt02.jpg"/></table-wrap>
    </p>
    <p content-type="asset">
      <table-wrap id="t03">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt03.jpg"/></table-wrap>
    </p>
    <p>Na an&#225;lise de regress&#227;o log&#237;stica para estabelecer as vari&#225;veis associadas de modo independente com a ocorr&#234;ncia de anemia, a ur&#233;ia foi a &#250;nica vari&#225;vel significativa quando analisada a popula&#231;&#227;o como um todo e quando a an&#225;lise incluiu somente o grupo PMF. Na popula&#231;&#227;o do HU, creatinina foi a &#250;nica vari&#225;vel associada de modo independente &#224; anemia (<xref ref-type="table" rid="t04">Tabela 4</xref>).</p>
    <p content-type="asset">
      <table-wrap id="t04">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt04.jpg"/></table-wrap>
    </p>
    <p>Houve um n&#250;mero grande de pacientes com fun&#231;&#227;o sist&#243;lica preservada, com predom&#237;nio no grupo PMF (<xref ref-type="table" rid="t01">tabela 1</xref>). Na popula&#231;&#227;o como um todo, 90 pacientes tinham ICFER e 119 ICFEN. A taxa de filtra&#231;&#227;o glomerular (TFG) foi menor no grupo com ICFER (57,6&#177;66,2 vs 94,8&#177;36,6 ml/min/1,73m<sup>2</sup>; p=0,01). N&#227;o houve diferen&#231;a na preval&#234;ncia da anemia nos dois grupos (23,3% vs 18,5%; p=0,34). A preval&#234;ncia da DR moderada a grave foi maior no grupo com ICFER (32,2% vs 16,8% p=0,01).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Na presente an&#225;lise, a anemia estava presente em 22,8% dos pacientes da popula&#231;&#227;o como um todo, em 25% no HU e em 21,1% no PMF, sem diferen&#231;a significativa entre os dois grupos. Dados de preval&#234;ncia variam muito de acordo com a defini&#231;&#227;o utilizada para anemia e de acordo com a popula&#231;&#227;o estudada. Nos estudos em que s&#227;o analisados pacientes com disfun&#231;&#227;o sist&#243;lica leve a moderada e em pacientes assintom&#225;ticos, os valores de preval&#234;ncia assemelham-se aos valores encontrados no presente estudo<sup>13,20</sup>.</p>
    <p>Para entender o problema da anemia na IC, &#233; importante conhecer os fatores que influenciam a preval&#234;ncia da anemia e conhecer a consist&#234;ncia da associa&#231;&#227;o da anemia e mortalidade nas v&#225;rias popula&#231;&#245;es de pacientes com IC. Revis&#227;o sistem&#225;tica publicada recentemente teve como objetivo avaliar a preval&#234;ncia da anemia, separando as publica&#231;&#245;es de acordo com a defini&#231;&#227;o de anemia utilizada, as caracter&#237;sticas cl&#237;nicas dos pacientes envolvidos, a preval&#234;ncia de anemia na amostra analisada e a associa&#231;&#227;o da anemia com mortalidade. Quando analisada a preval&#234;ncia da anemia em pacientes ambulatoriais, 10 estudos foram selecionados e as preval&#234;ncias variavam entre 15% a 61%<sup>29</sup>.</p>
    <p>Preval&#234;ncias t&#227;o distintas foram analisadas e a partir da compara&#231;&#227;o das caracter&#237;sticas cl&#237;nicas desses pacientes ambulatoriais (de diferentes centros), observou-se que a preval&#234;ncia da anemia era mais elevada nas popula&#231;&#245;es com m&#233;dias de idade maiores, IC de maior gravidade (estimada pela classifica&#231;&#227;o da NYHA) e maior preval&#234;ncia de comorbidades como diabetes (DM) e insufici&#234;ncia renal cr&#244;nica (IRC)<sup>29</sup>. Estudos que avaliaram a preval&#234;ncia de anemia em centros cl&#237;nicos ambulatoriais para tratamento de IC, encontraram preval&#234;ncias semelhantes &#224;s encontradas em nosso estudo, variando entre 15% a 30%<sup>29</sup>.</p>
    <p>Anemia parace ser comorbidade importante n&#227;o apenas em pacientes com ICFER, mas tamb&#233;m naqueles com ICFEN. Em um estudo que avaliou a preval&#234;ncia e a import&#226;ncia da anemia em 137 pacientes com ICFEN, encontrou-se alta preval&#234;ncia (40%) e associa&#231;&#227;o com pior progn&#243;stico<sup>30</sup>. Da mesma forma que em nosso estudo, nesse trabalho tamb&#233;m n&#227;o houve diferen&#231;a significativa na preval&#234;ncia de anemia em com ou sem FE reduzida, evidenciando que a anemia na IC pode ser bastante prevalente, independentemente da fra&#231;&#227;o de eje&#231;&#227;o.</p>
    <p>Nosso estudo confirma que a disfun&#231;&#227;o renal &#233; um fator independentemente relacionado &#224; anemia. A presen&#231;a de disfun&#231;&#227;o renal moderada ou grave (TFG&lt;60 mL/min) &#233; associada a diminui&#231;&#227;o da produ&#231;&#227;o de eritropoietina (EPO) e diminui&#231;&#227;o progressiva dos valores de hemoglobina<sup>10,13</sup>.</p>
    <p>A fun&#231;&#227;o renal diminu&#237;da pode estar associada a eventos adversos na IC, podendo ser um marcador de gravidade ou um reflexo de doen&#231;a renal coexistente<sup>31</sup>. Estudo que avaliou a fun&#231;&#227;o renal em pacientes sintom&#225;ticos e assintom&#225;ticos com disfun&#231;&#227;o sist&#243;lica de VE evidenciou que graus moderados de disfun&#231;&#227;o renal conferem progn&#243;stico ruim<sup>31</sup>.</p>
    <p>Em estudo recente, analisou-se o impacto da anemia no decl&#237;nio da fun&#231;&#227;o renal em pacientes com IC. R&#225;pida diminui&#231;&#227;o da fun&#231;&#227;o renal foi definida como a diminui&#231;&#227;o da TFG<underline>&gt;</underline>6 ml/min/1,73m<sup>2</sup>/ano. Foram avaliados 6.360 pacientes, com m&#233;dia de idade de 59 anos, sendo que 31% apresentavam insufici&#234;ncia renal cr&#244;nica e 6% apresentavam anemia. O tempo de seguimento foi de 2 anos e a anemia foi associada com a r&#225;pida diminui&#231;&#227;o da fun&#231;&#227;o renal em pacientes com IC, particularmente nos pacientes que j&#225; possu&#237;am fun&#231;&#227;o renal alterada<sup>32</sup>.</p>
    <p>A anemia &#233; freq&#252;entemente associada a reduzidos valores de IMC, um achado que sugere que pacientes com caquexia apresentam maior risco de anemia<sup>16</sup>. N&#237;veis s&#233;ricos de citocinas e de marcadores inflamat&#243;rios est&#227;o aumentados em pacientes com caquexia e podem contribuir para o desenvolvimento de anemia por diversos mecanismos<sup>16</sup>. No presente estudo, apesar de termo encontrados valores de IMC discretamente menores nos pacientes com anemia, n&#227;o houve associa&#231;&#227;o significativa desta vari&#225;vel com a anemia. Vale salientar que nenhum paciente em nosso estudo preenchia crit&#233;rios para caquexia ou desnutri&#231;&#227;o.</p>
    <p>A anemia tamb&#233;m pode estar relacionada ao uso de alguns medicamentos como os IECA e &#225;cido acetil salic&#237;lico<sup>22</sup>. Em nosso estudo n&#227;o encontramos associa&#231;&#227;o com estas medica&#231;&#245;es. No grupo PMF, no entanto, a utiliza&#231;&#227;o de diur&#233;ticos de al&#231;a foi mais freq&#252;ente no grupo com anemia que em n&#227;o an&#234;micos. Este achado provavelmente n&#227;o significa rela&#231;&#227;o causal e sim reflexo da piora da fun&#231;&#227;o renal, quando diur&#233;ticos tiaz&#237;dicos s&#227;o trocados para diur&#233;ticos de al&#231;a. No entanto, tem-se apontado poss&#237;vel papel dos diur&#233;ticos na piora da fun&#231;&#227;o renal em pacientes com IC<sup>33</sup>. Ainda n&#227;o est&#225; claro, portanto, se os diur&#233;ticos s&#227;o a causa da piora da fun&#231;&#227;o renal ou se funcionam como marcadores de risco, pelo fato de o seu uso estar relacionado a casos mais graves<sup>33</sup>.</p>
    <p>Como limita&#231;&#245;es de noso estudo, destacamos o fato de n&#227;o termos estudado todos os poss&#237;veis mecanismos de anemia. Embora a disfun&#231;&#227;o renal tenha-se mostrado relacionada &#224; presen&#231;a de anemia, n&#227;o podemos estabelecer uma rela&#231;&#227;o de causa e efeito, assim como n&#227;o podemos afirmar se mecanismos adicionais contribu&#237;ram para a ocorr&#234;ncia de anemia.</p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>A preval&#234;ncia de anemia em pacientes com IC acompanhados por m&#233;dicos de fam&#237;lia na comunidade, foi semelhante &#224; encontrada em um ambulat&#243;rio especializado em um hospital universit&#225;rio, mostrando que ela &#233; prevelente mesmo em popula&#231;&#245;es n&#227;o selecionadas. A fun&#231;&#227;o renal, atrav&#233;s de avalia&#231;&#227;o de ur&#233;ia ou creatinina, foi o &#250;nico fator relacionado de modo independente com a presen&#231;a de anemia nas duas popula&#231;&#245;es.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Eduarda Barcellos dos Santos pela Universidade Federal Fluminense.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Humberto Villacorta </p>
        <p> Rua Marqu&#234;s do Paran&#225; 303 - 6 andar - Cardiologia </p>
        <p> 24033-900 - Niter&#243;i, RJ, Brasil </p>
        <p> E-mail: : </p>
        <p>
          <email xlink:href="hvillacorta@cardiol.br">hvillacorta@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 09/12/08; revisado recebido em 28/05/09; aceito em 09/07/09.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. American Heart    Association. Heart Disease and Stroke Statistics: 2005 Update.</mixed-citation>
        <element-citation publication-type="book">
          <source>Heart Disease and Stroke Statistics</source>
          <date>
            <year>2005</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. O'Connell JB,    Bristow MR. Economic impact of heart failure in the United States: time for    a different approach. J Heart Lung Tranplant. 1994; 13: S107-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Economic impact of heart failure in the United States: time for a different approach</article-title>
          <source>J Heart Lung Tranplant</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>S107</fpage>
          <lpage>12</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>O'Connell</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Bristow</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Haldeman GA,    Croft JB, Giles WH, Rashidre A. Hospitalizations of patients with heart failure:    National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999; 137: 352-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hospitalizations of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>352</fpage>
          <lpage>60</lpage>
          <volume>137</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Haldeman</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Rashidre</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Minist&#233;rio da Sa&#250;de. Secretaria executiva. DATASUS: informa&#231;&#245;es de sa&#250;de: morbidade e informa&#231;&#245;es epidemiol&#243;gicas. [Acesso em 2006 maio 10]. Dispon&#237;vel em: URL: <ext-link ext-link-type="uri" xlink:href="http://www.datasus.gov.br">http://www.datasus.gov.br</ext-link>.</mixed-citation>
        <element-citation publication-type="book">
          <source>DATASUS: informa&#231;&#245;es de sa&#250;de: morbidade e informa&#231;&#245;es epidemiol&#243;gicas</source>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Ara&#250;jo    DV, Tavares LR, Ver&#237;ssimo R, Ferraz MB, Mesquira ET. Custo da insufici&#234;ncia    card&#237;aca no Sistema &#218;nico de Sa&#250;de. Arq Bras Cardiol. 2005;    84: 422-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Custo da insufici&#234;ncia card&#237;aca no Sistema &#218;nico de Sa&#250;de</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>422</fpage>
          <lpage>7</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ara&#250;jo</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Ver&#237;ssimo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mesquira</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Tavares LR,    Victer H, Linhares JM, Barros CM, Oliveira MV, Pacheco LC, et al. Epidemiologia    da insufici&#234;ncia card&#237;aca descompensada em Niter&#243;i: Projeto    EPICA-Niter&#243;i. Arq Bras Cardiol. 2004; 82: 121-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Epidemiologia da insufici&#234;ncia card&#237;aca descompensada em Niter&#243;i: Projeto EPICA-Niter&#243;i</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>121</fpage>
          <lpage>4</lpage>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Victer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Linhares</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Barros</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Pacheco</surname>
              <given-names>LC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Owan TE, Hodge    DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and    outcome of heart failure with preserved ejection fraction. N Eng J Med. 2006;    355: 251-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Trends in prevalence and outcome of heart failure with preserved ejection fraction</article-title>
          <source>N Eng J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>251</fpage>
          <lpage>9</lpage>
          <volume>355</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Owan</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Herges</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Roger</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Bursi F, Westar    SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic    heart failure in the community. JAMA 2006;296:2209-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Systolic and diastolic heart failure in the community</article-title>
          <source>JAMA</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2209</fpage>
          <lpage>16</lpage>
          <volume>296</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bursi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Westar</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Pakhomov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nkomo</surname>
              <given-names>VT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Aurigemma GP,    Gaasch WH. Diastolic heart failure. N Engl J Med. 2004; 351: 1097-105.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diastolic heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1097</fpage>
          <lpage>105</lpage>
          <volume>351</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aurigemma</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Silverberg    DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous    erythropoietin and intravenous iron for the treatment of the anemia of severe,    resistant congestive heart failure improves cardiac and renal function and functional    cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;    35: 1737-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1737</fpage>
          <lpage>44</lpage>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silverberg</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Wexler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keren</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sheps</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leibovitch</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Silverberg    DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction    of mild anemia in severe resistant heart failure using subcutaneous erythropoietin    and intravenous iron : a randomized controlled study. J Am Coll Cardiol. 2001;    37: 1775-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of correction of mild anemia in severe resistant heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1775</fpage>
          <lpage>80</lpage>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silverberg</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Wexler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sheps</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keren</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Baruch</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Silverberg    DS, Wexler D, Blum M. The effect of correction of anemia in diabetics and non    diabetics with severe resistent congestive heart failure and chronic renal failure    by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant.    2003; 18: 141-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of correction of anemia in diabetics and non diabetics with severe resistent congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>141</fpage>
          <lpage>6</lpage>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silverberg</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Wexler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Al-Ahmad A,    Rand SM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney    function and anemia as risk factors for mortality in patients with left ventricular    dysfunction. J Am Coll Cardiol. 2001; 38: 955-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>955</fpage>
          <lpage>62</lpage>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Al-Ahmad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rand</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Manjunath</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Salem</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Levey</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Mozaffarian    D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure. The Prospective    Randomized Amlodipine Survival Evaluation (PRAISE). J Am Coll Cardiol. 2003;    41: 1933-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia predicts mortality in severe heart failure: The Prospective Randomized Amlodipine Survival Evaluation (PRAISE)</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1933</fpage>
          <lpage>9</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mozaffarian</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nye</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Kosiborod M,    Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, et al. Anemia and outcomes    in patients with heart failure. Arch Intern Med. 2005; 165: 2237-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and outcomes in patients with heart failure</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2237</fpage>
          <lpage>44</lpage>
          <volume>165</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kosiborod</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Masoudi</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Foody</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Horwich TB,    Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with    worse symptoms, greater impairment in functional capacity and a significant    increase in mortality in patients with advanced heart failure. J Am Coll Cardiol.    2002; 39: 1780-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1780</fpage>
          <lpage>6</lpage>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Horwich</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>MacLellan</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Borenstein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Ezekowitz JA,    McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated    with poor outcomes. Insights from a cohort of 12065 patients with new-onset    heart failure. Circulation. 2003; 107: 223-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12065 patients with new-onset heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>223</fpage>
          <lpage>5</lpage>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ezekowitz</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McAlister</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Felker GM,    Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, et al. Usefulness    of anemia as a predictor of death and rehospitalization in patients with decompensated    heart failure. Am J Cardiol. 2003; 92: 625-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>625</fpage>
          <lpage>8</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Felker</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Gattis</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Leimberger</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Cuffe</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Sales AF, Villacorta    H, Reis L, Mesquita ET. Anemia as a prognostic factor in a population hospitalized    due to decompensated heart failure. Arq Bras Cardiol. 2005; 84: 237-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia as a prognostic factor in a population hospitalized due to decompensated heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>237</fpage>
          <lpage>40</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sales</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Villacorta</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Anand IS, Kuskowski    MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin    over time related to mortality and morbidity in patients with chronic heart    failure - results from Val-Heft. Circulation. 2005; 112: 1121-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure - results from Val-Heft</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1121</fpage>
          <lpage>7</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Kuskowski</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Florea</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Hester</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Anand I, McMurray    JJ, Whitmore J, Warren M, Pham A, McCamish MA, et al. Anemia and its relationship    to clinical outcome in heart failure. Circulation. 2004; 110: 149-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and its relationship to clinical outcome in heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>149</fpage>
          <lpage>54</lpage>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Whitmore</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McCamish</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Ishani A, Weinhandl    E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin-converting    enzyme inhibitor as a risk factor for the development of anemia, and the impact    of incident anemia on mortality in patients with left ventricular dysfunction.    J Am Coll Cardiol. 2005; 45: 391-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>391</fpage>
          <lpage>9</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ishani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weinhandl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Gilbertson</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Szachniewicz    J, Petruk-Kowalczyc J, Majda J, Kaczmarek A, Reczuch K, Kabia PR, et al. Anaemia    is an independent predictor of poor outcome in patients with chronic heart failure.    Int J Cardiol. 2003; 90: 303-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anaemia is an independent predictor of poor outcome in patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>303</fpage>
          <lpage>8</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Szachniewicz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Petruk-Kowalczyc</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Majda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaczmarek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reczuch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kabia</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Maggioni AP,    Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, et al. Anemia in patients    with heart failure: prevalence and prognostic role in a controlled trial and    in clinical practice. J Card Fail. 2005; 11: 91-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>91</fpage>
          <lpage>8</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maggioni</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Opasich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Anand</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barlera</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carbonieri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gonzini</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Sharma R, Francis    DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival    in patients with chronic heart failure: a substudy of the ELITE II trial. Eur    Heart J. 2004; 25: 1021-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1021</fpage>
          <lpage>8</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Pitt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Packer M, Fowler    MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the    morbidity of patients with severe chronic heart failure: results of the Carvedilol    Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Circulation.    2002; 106: 2194-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2194</fpage>
          <lpage>9</lpage>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Roecker</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Katus</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Krum</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. McClellan WM,    Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency    are independent risk factors for death among patients with congestive heart    failure admitted to community hospitals: a population-based study. J Am Soc    Nephrol. 2002; 13: 1928-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1928</fpage>
          <lpage>36</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McClellan</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Flanders</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Langston</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Jurkovitz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Presley</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Moutinho MA,    Colucci FA, Alcoforado V, Tavares LR, Rachi MB, Rosa ML, et al. Insufici&#234;ncia    card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o preservada    e com disfun&#231;&#227;o sist&#243;lica na comunidade. Arq Bras Cardiol.    2008; 90: 145-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o preservada e com disfun&#231;&#227;o sist&#243;lica na comunidade</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>145</fpage>
          <lpage>50</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moutinho</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Colucci</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Alcoforado</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Rachi</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Lindelfeld    J. Prevalence of anemia and effects on mortality in patients with heart failure.    Am Heart J. 2005; 149: 391-401.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of anemia and effects on mortality in patients with heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>391</fpage>
          <lpage>401</lpage>
          <volume>149</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lindelfeld</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Brucks S, Little    WC, Chao T, Rideman RL, Upadhya B, Wesley-Farrington D, et al. Relation of anemia    to diastolic heart failure and the effect on outcome. Am J Cardiol. 2004; 93:    1055-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of anemia to diastolic heart failure and the effect on outcome</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1055</fpage>
          <lpage>7</lpage>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brucks</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rideman</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Upadhya</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wesley-Farrington</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Hillege HL,    Nitsch D, Pfeffer MA, Swedberg K, McMurray JV, Yusuf S, et al. Renal function    as a predictor of outcome in a broad spectrum of patients with heart failure.    Circulation. 2006; 113: 671-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Renal function as a predictor of outcome in a broad spectrum of patients with heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>671</fpage>
          <lpage>8</lpage>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hillege</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Nitsch</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Bansal N, Tighionart    H, Wriner D, Griffith J, Vlagopoulos P, Salem D, et al. Anemia as a risk factor    for kidney function decline in individuals with heart failure. Am J Cardiol.    2007; 99: 1137-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia as a risk factor for kidney function decline in individuals with heart failure</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1137</fpage>
          <lpage>42</lpage>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bansal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tighionart</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wriner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Griffith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vlagopoulos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Salem</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Butler J, Forman    DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart    failure treatment and development of worsening renal function among hospitalized    patients. Am Heart J. 2004; 147 (2): 331-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relationship between heart failure treatment and development of worsening renal function among hospitalized patients</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>331</fpage>
          <lpage>8</lpage>
          <issue>2</issue>
          <volume>147</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Butler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Forman</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Massie</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Anemia e insuficiencia cardiaca en la comunidad: comparaci&#243;n con un consultorio especializado</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La anemia es com&#250;n en pacientes con insuficiencia cardiaca (IC). Su prevalencia en pacientes con IC en la comunidad es desconocida en nuestro medio. OBJETIVO: Evaluar la prevalencia y caracter&#237;sticas de pacientes con anemia en una poblaci&#243;n con IC no seleccionada en la comunidad, compar&#225;ndola a una poblaci&#243;n con IC atendida en un consultorio especializado. M&#201;TODOS: Estudio transversal, prospectivo, observacional, realizado de enero de 2006 a marzo de 2007. Los pacientes con IC cumpl&#237;an los criterios de Boston, con puntuaci&#243;n &gt;8. La anemia fue definida por los criterios de la Organizaci&#243;n Mundial de la Salud, como valores de hemoglobina &lt;13 g/dl para hombres y &lt;12 g/dl para mujeres. Se seleccionaron en forma aleatoria pacientes atendidos en un programa de atenci&#243;n primaria en la comunidad y pacientes atendidos en un consultorio de insuficiencia cardiaca en un hospital universitario. RESULTADOS: Fueron evaluados 206 pacientes con promedio de edad de 61,3&#177;13,1 a&#241;os, y un 53,4% de sexo femenino. La prevalencia de la anemia en la comunidad (n=114) fue de 21% y en el consultorio (n=92), de 25% (p=0,50). Los pacientes de la comunidad presentaban menor tasa de disfunci&#243;n renal (TFG&lt;60 ml/min/1,73-5), predominio de IC con fracci&#243;n de eyecci&#243;n normal y sexo femenino. Los par&#225;metros de funci&#243;n renal (urea o cretinina) se relacionaron de modo independiente con la anemia, en las dos poblaciones. CONCLUSI&#211;N: La prevalencia de la anemia fue semejante en las poblaciones estudiadas. La funci&#243;n renal fue el &#250;nico factor relacionado de modo independiente con la anemia en las dos poblaciones.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Anemia</kwd>
        <kwd>prevalencia</kwd>
        <kwd>insuficiencia cardiaca</kwd>
        <kwd>estudio comparativo</kwd>
        <kwd>consultorio hospitalario</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Anemia e insuficiencia cardiaca en la comunidad: comparaci&#243;n con un consultorio especializado</bold>
          </label>
          <p>
            <bold>Eduarda Barcellos dos Santos; Bol&#237;var Saenz Tello; Humberto Villacorta; Ana Luisa Ferreira Sales; Christiane Wiefels; Pedro Soares Teixeira; Luis Costa Lima Filho; Evandro Tinoco Mesquita</bold>
          </p>
        </fn>
      </p>
      <p>Universidade Federal Fluminense, Niter&#243;i, RJ - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La anemia es com&#250;n en pacientes con insuficiencia cardiaca (IC). Su prevalencia en pacientes con IC en la comunidad es desconocida en nuestro medio.</p>
      <p><bold>OBJETIVO: </bold> Evaluar la prevalencia y caracter&#237;sticas de pacientes con anemia en una poblaci&#243;n con IC no seleccionada en la comunidad, compar&#225;ndola a una poblaci&#243;n con IC atendida en un consultorio especializado.</p>
      <p><bold>M&#201;TODOS: </bold> Estudio transversal, prospectivo, observacional, realizado de enero de 2006 a marzo de 2007. Los pacientes con IC cumpl&#237;an los criterios de Boston, con puntuaci&#243;n <underline>&gt;</underline>8. La anemia fue definida por los criterios de la Organizaci&#243;n Mundial de la Salud, como valores de hemoglobina &lt;13 g/dl para hombres y &lt;12 g/dl para mujeres. Se seleccionaron en forma aleatoria pacientes atendidos en un programa de atenci&#243;n primaria en la comunidad y pacientes atendidos en un consultorio de insuficiencia cardiaca en un hospital universitario.</p>
      <p><bold>RESULTADOS: </bold> Fueron evaluados 206 pacientes con promedio de edad de 61,3&#177;13,1 a&#241;os, y un 53,4% de sexo femenino. La prevalencia de la anemia en la comunidad (n=114) fue de 21% y en el consultorio (n=92), de 25% (p=0,50). Los pacientes de la comunidad presentaban menor tasa de disfunci&#243;n renal (TFG&lt;60 ml/min/1,73-5), predominio de IC con fracci&#243;n de eyecci&#243;n normal y sexo femenino. Los par&#225;metros de funci&#243;n renal (urea o cretinina) se relacionaron de modo independiente con la anemia, en las dos poblaciones.</p>
      <p><bold>CONCLUSI&#211;N:</bold> La prevalencia de la anemia fue semejante en las poblaciones estudiadas. La funci&#243;n renal fue el &#250;nico factor relacionado de modo independiente con la anemia en las dos poblaciones. (Arq Bras Cardiol 2010; 94(1) : 96-102)</p>
      <p><bold>Palabras clave: </bold> Anemia, prevalencia, insuficiencia cardiaca, estudio comparativo, consultorio hospitalario.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca (IC) est&#225; considerada como un problema de la salud p&#250;blica en los Estados Unidos<sup>1</sup>. Esta patolog&#237;a constituye la causa principal de las visitas a consultorios m&#233;dicos y hay un n&#250;mero cada vez mayor de hospitalizaciones<sup>2,3</sup>.</p>
      <p>En Brasil, la IC constituye el tercer motivo de internaci&#243;n entre todas las causas y el primero entre las enfermedades cardiovasculares (ECV) en el Sistema &#218;nico de Salud (SUS), en pacientes mayores de 65 a&#241;os, elevando los costos con esta patolog&#237;a<sup>4,5</sup>. El impacto en el sistema p&#250;blico brasile&#241;o tambi&#233;n puede ser estimado a trav&#233;s de los datos de un estudio, donde se evaluaron las internaciones por IC en hospitales p&#250;blicos y privados en una ciudad brasile&#241;a en el a&#241;o 2001, mostrando que los pacientes atendidos en hospitales p&#250;blicos son en promedio 10 a&#241;os m&#225;s j&#243;venes y presentan mayor tiempo de internaci&#243;n hospitalaria que los de la red privada<sup>6</sup>.</p>
      <p>Estudios poblacionales muestran que la IC tiene alta prevalencia en la comunidad, con predominio de la IC con fracci&#243;n de eyecci&#243;n normal (ICFEN)<sup>7,8</sup>. Aun cuando la ICFEN haya sido considerada en el pasado una patolog&#237;a de menor gravedad, los datos actuales muestran su importancia cl&#237;nica por el incremento del 5% al 8% en la mortalidad anual (comparado a un intervalo del 10% al 15% de la IC con fracci&#243;n de eyecci&#243;n reducida)<sup>9</sup>.</p>
      <p>La anemia es com&#250;n en los pacientes con IC y se viene proponiendo como un nuevo objetivo terap&#233;utico en esta poblaci&#243;n. Silverberg et al<sup>10-12</sup> fueron los primeros en detallar el papel de la anemia en la IC e introdujeron el concepto de que la correcci&#243;n de la anemia podr&#237;a contribuir a la mejor&#237;a cl&#237;nica de los pacientes con IC<sup>10-12</sup>.</p>
      <p>Condici&#243;n com&#250;n en los pacientes con IC, particularmente en los ancianos, la anemia aumenta su prevalencia cuanto mayor es la gravedad de la patolog&#237;a<sup>10-12</sup>. La prevalencia de anemia en pacientes con IC var&#237;a del 4% al 62% en la literatura<sup>13-20</sup>. Los resultados tan variados se deben a los diferentes criterios utilizados para el diagn&#243;stico de anemia y a las diferentes poblaciones estudiadas.</p>
      <p>Diversos estudios vienen estableciendo que la presencia de anemia en pacientes con IC est&#225; asociada a un peor pron&#243;stico y a mayor morbilidad y mortalidad cardiovascular<sup>13-27</sup>.</p>
      <p>En nuestro medio hay pocos estudios de la anemia en la comunidad. La ventaja de esos estudios es obtener datos de poblaciones no seleccionadas, a diferencia de estudios en ambientes terciarios, donde se atienden pacientes m&#225;s graves. En un estudio nacional reciente, se confirm&#243; que, en nuestro medio, en la comunidad predomina la ICFEN sobre la IC con fracci&#243;n de eyecci&#243;n reducida (ICFER)<sup>28</sup>, lo que difiere de lo observado en servicios de referencia para IC.</p>
      <p>El objetivo de este trabajo fue determinar la prevalencia y las caracter&#237;sticas cl&#237;nicas de pacientes portadores de anemia en una poblaci&#243;n con IC cr&#243;nica en la comunidad, compar&#225;ndolas a las de pacientes atendidos en un consultorio especializado en IC.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Este fue un estudio observacional, transversal, prospectivo, que comprendi&#243; pacientes con diagn&#243;stico de IC, pertenecientes a un programa de m&#233;dicos de familia (PMF) y pacientes de un consultorio especializado de un hospital universitario (HU). Se realizaron visitas a los centros de salud del PMF, de diferentes barrios, para catalogar los casos sospechosos de IC, en individuos con edad superior a 18 a&#241;os identificados por los m&#233;dicos generalistas. Las informaciones se recolectaron a trav&#233;s de cuestionarios con datos de la historia cl&#237;nica, datos demogr&#225;ficos, h&#225;bitos de vida, examen f&#237;sico, datos antropom&#233;tricos, cuantificaci&#243;n de la clase funcional (CF) seg&#250;n los criterios de la <italic>New York Heart Association</italic> (NYHA) y an&#225;lisis de los ex&#225;menes complementarios (electrocardiograma, radiograf&#237;a de t&#243;rax y ecocardiograma doppler) y medicamentos en uso. Los pacientes eran remitidos al consultorio de IC del HU, para complementaci&#243;n de los datos del cuestionario, que eventualmente no pudiesen ser obtenidos en el d&#237;a de la visita al centro de salud.</p>
      <p>A todos los pacientes se les realiz&#243; un ecocardiograma doppler. Aquellos que no dispon&#237;an del examen, fueron sometidos a esta evaluaci&#243;n en el servicio de ecocardiograf&#237;a del HU. Se midi&#243; la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) por el m&#233;todo de Simpson y se clasificaron los pacientes en portadores de ICFER, cuando presentaban FEVI &lt;50% y portadores de ICFEN cuando &#233;sta era <underline>&gt;</underline>50%.</p>
      <p>Los pacientes del HU ya ten&#237;an diagn&#243;stico de IC y estaban adecuadamente medicados. En el momento de acordar formar parte del estudio, fueron sometidos a nuevos ex&#225;menes de laboratorio y de im&#225;genes. Todos los pacientes con diagn&#243;stico de IC cumpl&#237;an con los criterios de Boston para IC con puntuaci&#243;n mayor o igual a 8. El per&#237;odo de inclusi&#243;n del estudio fue de enero de 2006 a marzo de 2007. Fueron excluidos pacientes con enfermedad renal avanzada (tratamiento con di&#225;lisis).</p>
      <p>La anemia fue definida seg&#250;n los criterios de la Organizaci&#243;n Mundial de la Salud (OMS) que caracterizan como an&#233;micos hombres con hemoglobina s&#233;rica &lt;13 g/dl y mujeres con valores &lt;12 g/dl. La funci&#243;n renal se evalu&#243; a trav&#233;s de la urea y la creatinina s&#233;ricas y por la tasa de filtrado glomerular (TFG) estimada, calculada mediante la f&#243;rmula sMDRD (<italic>Simplified Modified Diet Renal Disease</italic>). Esta f&#243;rmula fue validada en varios estudios, en diferentes poblaciones y se utiliz&#243; para estimar la TFG en pacientes con IC. La obesidad fue definida como la presencia de &#237;ndice de masa corporal (IMC) &gt; 30 y desnutrici&#243;n como IMC &lt; 17.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables continuas se expresaron como promedios y sus respectivos desviaci&#243;n est&#225;ndar y fueron comparadas mediante el test <italic>t</italic> de <italic>Student</italic>. Las variables categ&#243;ricas se expresaron bajo la forma de valores absolutos y porcentaje y fueron comparadas utilizando el test de chi-cuadrado o test exacto de Fischer para las muestras con valores esperados menores que 5. Las variables con valor de p&lt;0,10 en el an&#225;lisis univariado fueron incluidas en el an&#225;lisis multivariado (regresi&#243;n log&#237;stica), con el objetivo de verificar cu&#225;les presentaban relaci&#243;n independiente con la presencia de anemia. El an&#225;lisis fue realizado con los programas estad&#237;sticos EPIINFO 3.4 y SPSS, versi&#243;n 11.0. Se consideraron estad&#237;sticamente significativos valores de p&lt;0,05. El criterio de determinaci&#243;n de significancia adoptado fue el nivel del 5%.</p>
      <p>
        <bold>Bio&#233;tica</bold>
      </p>
      <p>El estudio fue aprobado por el Comit&#233; de &#201;tica en Investigaci&#243;n de nuestro hospital. Todos los participantes cumplieron con el formulario de consentimiento informado y el estudio estuvo de acuerdo con la Declaraci&#243;n de Helsinki.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>El estudio comprendi&#243; 206 pacientes con diagn&#243;stico de IC, de 2 poblaciones distintas (consultorio especializado y de la comunidad). El promedio de edad fue de 61,3&#177;13 a&#241;os, con un 53,4% (110) de sexo femenino. En 47 (22,8%) de los 206 pacientes se observ&#243; la presencia de anemia. Cuando comparamos las prevalencias de anemia en las dos poblaciones, observamos que, a pesar de haber sido discretamente superior en el grupo HU (23 [25%] <italic>vs</italic> 24 [21%]), no hubo diferencia estad&#237;sticamente significativa (<xref ref-type="fig" rid="f1-body2">Figura 1</xref>).</p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gf01-es.jpg"/></fig>
      <p>La <xref ref-type="table" rid="es_16t01-body2">Tabla 1</xref> muestra las caracter&#237;sticas cl&#237;nicas y demogr&#225;ficas de las dos poblaciones. En el grupo HU hubo predominio del sexo masculino, mayor prevalencia de arteriopat&#237;a coronaria (AC), peor funci&#243;n renal, peor fracci&#243;n de eyecci&#243;n y presentaci&#243;n con menores valores de frecuencia cardiaca y presi&#243;n arterial sist&#243;lica (PAS) y diast&#243;lica (PAD). En el grupo PMF hubo predominio de sexo femenino, mayor prevalencia de hipertensi&#243;n arterial sist&#233;mica (HAS), dislipidemia y accidente cerebrovascular previo. En el HU predomin&#243; la disfunci&#243;n sist&#243;lica de VI (54,3%), observ&#225;ndose lo opuesto en el grupo PMF, con prevalencia del 82,4% de ICFEN. Hab&#237;a mayor utilizaci&#243;n de betabloqueantes, digoxina y diur&#233;ticos del asa en el HU.</p>
      <p content-type="asset">
        <table-wrap id="es_16t01-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt01-es.jpg"/></table-wrap>
      </p>
      <p>Las <xref ref-type="table" rid="es_16t02-body2">tablas 2</xref> y <xref ref-type="table" rid="es_16t03-body2">3</xref>, muestran las caracter&#237;sticas basales de pacientes an&#233;micos y no an&#233;micos en las dos poblaciones, respectivamente. Se observa que en el grupo PMF, la anemia estaba asociada a menor PAS, presencia de edema perif&#233;rico, menores niveles de colesterol total, menor fracci&#243;n de eyecci&#243;n, mayores valores de urea plasm&#225;tica y mayor uso de digoxina y diur&#233;ticos del asa. En el grupo HU, hab&#237;a asociaci&#243;n con niveles de creatinina s&#233;rica y tasa de filtrado glomerular.</p>
      <p content-type="asset">
        <table-wrap id="es_16t02-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt02-es.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="es_16t03-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt03-es.jpg"/></table-wrap>
      </p>
      <p>En el an&#225;lisis de regresi&#243;n log&#237;stica para establecer las variables asociadas de modo independiente con la ocurrencia de anemia, la urea fue la &#250;nica variable significativa cuando se analiz&#243; la poblaci&#243;n como un todo y cuando el an&#225;lisis incluy&#243; solamente el grupo PMF. En la poblaci&#243;n del HU, la creatinina fue la &#250;nica variable asociada de modo independiente a la anemia (<xref ref-type="table" rid="es_16t04-body2">Tabla 4</xref>).</p>
      <p content-type="asset">
        <table-wrap id="es_16t04-body2">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt04-es.jpg"/></table-wrap>
      </p>
      <p>Hubo un n&#250;mero grande de pacientes con funci&#243;n sist&#243;lica preservada, con predominio en el grupo PMF (<xref ref-type="table" rid="es_16t01-body2">tabla 1</xref>). En la poblaci&#243;n como un todo, 90 pacientes ten&#237;an ICFER y 119 ICFEN. La tasa de filtrado glomerular (TFG) fue menor en el grupo con ICFER (57,6&#177;66,2 <italic>vs</italic> 94,8&#177;36,6 ml/min/1,73m<sup>2</sup>; p=0,01). No hubo diferencia en la prevalencia de la anemia en los dos grupos (23,3% <italic>vs</italic> 18,5%; p=0,34). La prevalencia de la DR moderada a grave fue mayor en el grupo con ICFER (32,2% <italic>vs</italic> 16,8% p=0,01).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En el presente an&#225;lisis, la anemia ocurri&#243; en el 22,8% de los pacientes de la poblaci&#243;n como un todo, en un 25% en el HU y en el 21,1% en el PMF, sin diferencia significativa entre los dos grupos. Los datos de prevalencia var&#237;an mucho seg&#250;n la definici&#243;n utilizada para anemia y seg&#250;n la poblaci&#243;n estudiada. En los estudios en que se analizan pacientes con disfunci&#243;n sist&#243;lica leve a moderada y en pacientes asintom&#225;ticos, los valores de prevalencia se asemejan a los valores encontrados en el presente estudio<sup>13,20</sup>.</p>
      <p>Para entender el problema de la anemia en la IC, es importante conocer los factores que influyen sobre la prevalencia de la anemia y conocer la consistencia de la asociaci&#243;n de la anemia y la mortalidad en las diferentes poblaciones de pacientes con IC. Una revisi&#243;n sistem&#225;tica publicada recientemente tuvo como objetivo evaluar la prevalencia de la anemia, separando las publicaciones de acuerdo con la definici&#243;n de anemia utilizada, las caracter&#237;sticas cl&#237;nicas de los pacientes incluidos, la prevalencia de anemia en la muestra analizada y la asociaci&#243;n de la anemia con mortalidad. Cuando se analiz&#243; la prevalencia de la anemia en pacientes ambulatorios, se seleccionaron 10 estudios y la prevalencia vari&#243; entre el 15% y el 61%<sup>29</sup>.</p>
      <p>Se analizaron los porcentajes tan distintos de prevalencia y a partir de la comparaci&#243;n de las caracter&#237;sticas cl&#237;nicas de estos pacientes ambulatorios (de diferentes centros), se observ&#243; que la prevalencia da anemia era m&#225;s elevada en las poblaciones con promedios de edad mayores, IC de mayor gravedad (estimada por la clasificaci&#243;n de la NYHA) y mayor prevalencia de comorbilidades como diabetes (DM) e insuficiencia renal cr&#243;nica (IRC)<sup>29</sup>. Estudios que evaluaron la prevalencia de anemia en centros cl&#237;nicos ambulatorios para tratamiento de la IC, encontraron tasas de prevalencia semejantes a las encontradas en nuestro estudio, variando entre el 15% y el 30%<sup>29</sup>.</p>
      <p>La anemia parece ser una comorbilidad importante, no s&#243;lo en pacientes con ICFER, sino tambi&#233;n en aquellos con ICFEN. En un estudio que evalu&#243; la prevalencia y la importancia de la anemia en 137 pacientes con ICFEN, se hall&#243; una alta prevalencia (40%) y asociaci&#243;n con peor pron&#243;stico<sup>30</sup>. De la misma forma que en nuestro estudio, en ese trabajo tampoco hubo diferencia significativa en la prevalencia de anemia en IC con o sin FE reducida, evidenciando que la anemia en la IC puede ser bastante prevalente, independientemente de la fracci&#243;n de eyecci&#243;n.</p>
      <p>Nuestro estudio confirma que la disfunci&#243;n renal es un factor independientemente relacionado a la anemia. La presencia de disfunci&#243;n renal moderada o grave (TFG&lt;60 ml/min) est&#225; asociada a disminuci&#243;n de la producci&#243;n de eritropoyetina (EPO) y disminuci&#243;n progresiva de los valores de hemoglobina<sup>10,13</sup>.</p>
      <p>La funci&#243;n renal disminuida puede estar asociada a eventos adversos en la IC, y ser un marcador de gravedad o un reflejo de patolog&#237;a renal coexistente<sup>31</sup>. Un estudio que evalu&#243; la funci&#243;n renal en pacientes sintom&#225;ticos y asintom&#225;ticos con disfunci&#243;n sist&#243;lica de VI evidenci&#243; que los grados moderados de disfunci&#243;n renal confieren un mal pron&#243;stico<sup>31</sup>.</p>
      <p>En un estudio reciente, se analiz&#243; el impacto de la anemia en el deterioro de la funci&#243;n renal en pacientes con IC. La r&#225;pida disminuci&#243;n de la funci&#243;n renal fue definida como la disminuci&#243;n de la TFG<underline>&gt;</underline>6 ml/min/1,73m<sup>2</sup>/a&#241;o. Se evaluaron 6.360 pacientes, con un promedio de edad de 59 a&#241;os, de los que el 31% presentaba insuficiencia renal cr&#243;nica y el 6% presentaba anemia. El tiempo de seguimiento fue de 2 a&#241;os y la anemia se asoci&#243; con el r&#225;pido deterioro de la funci&#243;n renal en pacientes con IC, particularmente en los pacientes que ya ten&#237;an la funci&#243;n renal alterada<sup>32</sup>.</p>
      <p>La anemia est&#225; frecuentemente asociada a reducidos valores de IMC, un hallazgo que sugiere que pacientes con caquexia presentan mayor riesgo de anemia<sup>16</sup>. Los niveles s&#233;ricos de citocinas y de marcadores inflamatorios est&#225;n aumentados en pacientes con caquexia y pueden contribuir a la aparici&#243;n de anemia por diversos mecanismos<sup>16</sup>. En el presente estudio, a pesar de haberse encontrado valores de IMC discretamente menores en los pacientes con anemia, no existi&#243; asociaci&#243;n significativa de esta variable con la anemia. Cabe destacar que ning&#250;n paciente en nuestro estudio cumpl&#237;a los criterios para caquexia o desnutrici&#243;n.</p>
      <p>La anemia tambi&#233;n puede estar relacionada al uso de algunos medicamentos como los IECA y el &#225;cido acetilsalic&#237;lico<sup>22</sup>. En nuestro estudio no encontramos asociaci&#243;n con estos medicamentos. En el grupo PMF, no obstante, la utilizaci&#243;n de diur&#233;ticos del asa fue m&#225;s frecuente en el grupo con anemia que en los no an&#233;micos. Este hallazgo probablemente no significa relaci&#243;n causal y s&#237; refleja un empeoramiento de la funci&#243;n renal, cuando se cambia los diur&#233;ticos tiaz&#237;dicos por diur&#233;ticos de asa. Sin embargo, se ha se&#241;alado un posible papel de los diur&#233;ticos en el deterioro de la funci&#243;n renal en pacientes con IC<sup>33</sup>. A&#250;n no est&#225; claro, por lo tanto, si los diur&#233;ticos son la causa de la disminuci&#243;n de la funci&#243;n renal o si funcionan como marcadores de riesgo, por el hecho estar relacionada su utilizaci&#243;n a casos m&#225;s graves<sup>33</sup>.</p>
      <p>Como limitaciones de nuestro estudio, destacamos el hecho de no haber estudiado todos los posibles mecanismos de anemia. A&#250;n cuando la disfunci&#243;n renal apareci&#243; relacionada a la presencia de anemia, no podemos establecer una relaci&#243;n de causa-efecto, as&#237; como no podemos afirmar si hubo mecanismos adicionales que contribuyeron a la aparici&#243;n de anemia.</p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>La prevalencia de anemia en pacientes con IC acompa&#241;ados por m&#233;dicos de familia en la comunidad, fue semejante a la hallada en un consultorio especializado en un hospital universitario, mostrando su prevalencia a&#250;n en poblaciones no seleccionadas. La funci&#243;n renal, a trav&#233;s de la evaluaci&#243;n de urea o creatinina, fue el &#250;nico factor relacionado de modo independiente a la presencia de anemia en las dos poblaciones.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de la disertaci&#243;n de Maestr&#237;a de Eduarda Barcellos dos Santos por la Universidad Federal Fluminense.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Anemia and heart failure in a community-based cohort: comparison with a specialized outpatient clinic</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Anemia is common in patients with heart failure (HF). Its prevalence in patients with HF from a community-based cohort is unknown in our country. OBJECTIVE: evaluate the prevalence and characteristics of patients with anemia in a non-selected population with HF from a community-based cohort, comparing it with that of a HF population treated at a specialized outpatient clinic. METHODS: This was a transversal, prospective, observational study, carried out from January 2006 to March 2007. The patients with HF met the Boston criteria, with a score &gt; 8. Anemia was defined through the criteria of the World Health Organization as hemoglobin levels &lt; 13 g/dL for men and &lt;12 g/dl for women. Patients treated at a primary care program in the community were randomly selected, as well as patients treated at a Heart Failure Outpatient Clinic in a university hospital. RESULTS: A total of 206 patients were assessed, with a mean age of 61.3&#177;13.1 years, of which 53.4% were females. The prevalence of anemia in the community-based cohort (n=114) was 21% and at the outpatient clinic (n=92), of 25% (p=0.50). The patients from the community-based cohort presented a lower rate of kidney dysfunction (GFR&lt;60 ml/min/1,73-5), predominance of HF with normal ejection fraction and female sex. Kidney function parameters (urea or creatinine) independently correlated with anemia in both populations. CONCLUSION: The prevalence of anemia was similar in the studied populations. Kidney function was the only factor that independently correlated with anemia in both populations.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Anemia</kwd>
        <kwd>prevalence</kwd>
        <kwd>heart failure</kwd>
        <kwd>comparative study</kwd>
        <kwd>outpatient clinics</kwd>
        <kwd>hospital</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Anemia and heart failure in a community-based cohort: comparison with a specialized outpatient clinic</bold>
          </label>
          <p>
            <bold>Eduarda Barcellos dos Santos; Bol&#237;var Saenz Tello; Humberto Villacorta; Ana Luisa Ferreira Sales; Christiane Wiefels; Pedro Soares Teixeira; Luis Costa Lima Filho, Evandro Tinoco Mesquita</bold>
          </p>
        </fn>
      </p>
      <p>Universidade Federal Fluminense, Niter&#243;i, RJ - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND: </bold> Anemia is common in patients with heart failure (HF). Its prevalence in patients with HF from a community-based cohort is unknown in our country.</p>
      <p><bold>OBJECTIVES: </bold> To evaluate the prevalence and characteristics of patients with anemia in a non-selected population with HF from a community-based cohort, comparing it with that of a HF population treated at a specialized outpatient clinic.</p>
      <p><bold>METHODS: </bold> This was a transversal, prospective, observational study, carried out from January 2006 to March 2007. The patients with HF met the Boston criteria, with a score <underline>&gt;</underline> 8. Anemia was defined through the criteria of the World Health Organization as hemoglobin levels &lt; 13 g/dL for men and &lt;12 g/dL for women. Patients treated at a primary care program in the community were randomly selected, as well as patients treated at a Heart Failure Outpatient Clinic in a university hospital.</p>
      <p><bold>RESULTS: </bold> A total of 206 patients were assessed, with a mean age of 61.3&#177;13.1 years, of which 53.4% were females. The prevalence of anemia in the community-based cohort (n=114) was 21% and at the outpatient clinic (n=92), of 25% (p=0.50). The patients from the community-based cohort presented a lower rate of kidney dysfunction (GFR&lt;60 mL/min/1,73<sup>-5</sup>), predominance of HF with normal ejection fraction and female sex. Kidney function parameters (urea or creatinine) independently correlated with anemia in both populations.</p>
      <p><bold>CONCLUSION: </bold> The prevalence of anemia was similar in the studied populations. Kidney function was the only factor that independently correlated with anemia in both populations.</p>
      <p><bold>Key-Words:</bold> Anemia; prevalence; heart failure; comparative study; outpatient clinics, hospital.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Herat failure (HF) is considered a public health problem in the United States<sup>1</sup> The disease is the main reason for seeking medical help and there is a growing number of hospital admissions due to it<sup>2,3</sup>.</p>
      <p>In Brazil, HF is the third major reason for hospital admissions among all causes and the first among cardiovascular diseases (CVD) at the Brazilian Public Health System (SUS) in patients older than 65 years, which increases the costs of the disease<sup>4,5</sup>. The impact on the Brazilian public health system can also evaluated through a study which assessed hospital admissions due to HF in public and private hospitals of a Brazilian city in 2001, showing that the patients treated in public hospitals are, on average, 10 years younger and present longer hospital stays than those from private hospitals<sup>6</sup>.</p>
      <p>Population studies show that the HF has a high prevalence in the community, with a predominance of HF with normal ejection fraction (HFNEF)<sup>7,8</sup>. Although HFNEF used to be seen as a minor disease in the past, current data show its clinical importance due to the increase in the annual mortality from 5% to 8% (compared to 10% to 15% of HF with decreased ejection fraction - HFDEF)<sup>9</sup>.</p>
      <p>Anemia is a common finding in patients with HF and it has been proposed as a new therapeutic target in this population. Silverberg et al<sup>10-12</sup> were the first to detail the role of anemia in HF and introduced the concept that the correction of anemia can contribute to a clinical improvement of patients with HF<sup>10-12</sup>.</p>
      <p>A common condition in patients with HF, particularly among the elderly, anemia has a higher prevalence when the disease is more severe<sup>10-12</sup>. The prevalence of anemia in patients with HF varies from 4% to 62% in literature<sup>13-20</sup>. Such varied results are due to the different criteria used to diagnose anemia and the different populations studied.</p>
      <p>Several studies have established that the presence of anemia in patients with HF is associated to a worse prognosis and a higher cardiovascular morbidity and mortality<sup>13-27</sup>.</p>
      <p>There have been few studies in our country on the prevalence of anemia in communities. The advantage of these studies is to obtain data from non-selected populations, differently from studies carried out in tertiary environments, where more severe patients are treated. A recent national study confirmed that, in the studied community, there was a predominance of HFNEF in relation to HFDEF<sup>28</sup>, which differs from what has been observed in Reference Services for HF.</p>
      <p>The objective of this study was to determine the prevalence and the clinical characteristics of patients with anemia in a population with chronic HF from a community-based cohort, comparing these data with those obtained from patients treated at an outpatient clinical specialized in HF.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>This was an observational, transversal, prospective study, which included patients with a diagnosis of HF that were treated at a Family Medicine Program (FMP) and patients from an outpatient clinic specialized in HF from a university hospital (UH). The Basic Health Units (BHU) of the FMP from different districts were visited in order to catalogue the cases suspected of having HF, among individuals aged 18 and older, identified by family physicians. The information was collected through questionnaires that contained clinical history data, life style habits, physical examination, anthropometric data, functional class (FC) assessment according to the New York Heart Association (NYHA) and analysis of complementary examinations (electrocardiogram, chest x-ray and Doppler echocardiogram) and current medications. The patients were referred to the HF outpatient clinic of UH for data completion of the questionnaire, when they could not be obtained during the visit to the BHU.</p>
      <p>The Doppler echocardiogram was carried out in all patients. Those that had not undergone the test were submitted to it at the Echocardiography Service of the UH. The left ventricular ejection fraction (LVEF) was measured by the Simpson method and patients were classified as having HFDEF when LVEF was &lt; 50% and HFNEF when it was <underline>&gt;</underline>50%.</p>
      <p>The patients from the UH had received a prior diagnosis of HF and used adequate medication. They were submitted to new laboratory and imaging assessment when they agreed to participate in the study. All patients with a diagnosis of HF met the Boston criteria for HF with a score <underline>&gt;</underline>8. The study inclusion period was January 2006 to March 2007. Patients with advanced-stage kidney disease (undergoing dialytic therapy) were excluded.</p>
      <p>Anemia was defined according to the criteria defined by the World Health Organization (WHO), which characterize as anemic male individuals with serum hemoglobin &lt;13 g/dL and female individuals with values &lt;12 g/dL. Kidney function was evaluated through serum urea and creatinine levels and the estimated glomerular filtration rate (GFR), calculated through the sMDRD (Simplified Modification of Diet in Renal Disease) formula.</p>
      <p>This formula has been validated in many studies, in different populations and it has been used to estimate GFR in patients with HF. Obesity was defined as the presence of body mass index (BMI) &gt; 30 and malnutrition as BMI &lt; 17.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>The continuous variables were expressed as means and their respective standard deviations and compared using Student's <italic>t</italic> test. The categorical variables were expressed as absolute values and percentages and were compared by Chi-square test or Fisher's Exact Test for samples with expected values &lt; 5. The variables with p value &lt; 0.10 at the univariate analysis were included in the multivariate analysis (logistic regression), with the objective of verifying which ones presented an independent association with the presence of anemia. The analysis was carried out with the statistical programs EPIINFO 3.4 and SPSS, version 11.0. P values &lt;0.05 were considered statistically significant. The criterion for significance determination was established at 5%.</p>
      <p>
        <bold>Bioethics</bold>
      </p>
      <p>The study was approved by the Ethics Committee in Research of our hospital and it is in accordance with the Declaration of Helsinki; all participants gave their free and informed consent.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The study included 206 patients with a diagnosis of HF, from 2 distinct populations (specialized outpatient clinic and a community-based cohort). Mean age was 61.3&#177;13 years and 53.4% (110) of the studied individuals were females. The presence of anemia was observed in 47 (22.8%) of the 206 patients. When comparing the prevalence of anemia in the two populations, we observed that, although the prevalence was slightly higher in the UH group (23 [25%] <italic>vs.</italic> 24 [21%]), there was no statistically significant difference between them (<xref ref-type="fig" rid="f1-body3">Figure 1</xref>).</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gf01-en.jpg"/></fig>
      <p><xref ref-type="table" rid="en_16t01-body3">Table 1</xref> shows the clinical and demographic characteristics of the two populations. In the UH, there was a predominance of the male sex, a higher prevalence of coronary artery disease (CAD), worse kidney function, worse ejection fraction (EF) and lower values of heart rate (HR), systolic arterial pressure (SAP) and diastolic arterial pressure (DAP). In the FMP group, there was a predominance of the female sex, higher prevalence of systemic arterial hypertension (SAH), dyslipidemia and cerebrovascular accident (CVA). In the UH group, there was a predominance of LV systolic dysfunction (54.3%), whereas the opposite was observed in the FMP group, with a prevalence of 82.4% of HFNEF. The UH group presented a higher incidence of use of beta-blockers, digoxin and loop diuretics.</p>
      <p content-type="asset">
        <table-wrap id="en_16t01-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt01-en.jpg"/></table-wrap>
      </p>
      <p><xref ref-type="table" rid="en_16t02-body3">Tables 2</xref> and <xref ref-type="table" rid="en_16t03-body3">3</xref> show the basal characteristics of anemic and non-anemic patients in the two populations, respectively. It can be observed that in the FMP group, anemia was associated with a lower SAP, presence of peripheral edema, lower levels of total cholesterol, lower EF, higher levels of plasma urea and higher incidence of use of digoxin and loop diuretics. In the UH group, there was an association with levels of serum creatinine and glomerular filtration rate.</p>
      <p content-type="asset">
        <table-wrap id="en_16t02-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt02-en.jpg"/></table-wrap>
      </p>
      <p content-type="asset">
        <table-wrap id="en_16t03-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt03-en.jpg"/></table-wrap>
      </p>
      <p>At the logistic regression analysis, used to establish the variables independently associated with the occurrence of anemia, urea was the only significant variable when the population was analyzed as a whole and when the analysis included only the FMP group. In the UH population, creatinine was the only variable independently associated with anemia (<xref ref-type="table" rid="en_16t04-body3">Table 4</xref>).</p>
      <p content-type="asset">
        <table-wrap id="en_16t04-body3">
          <graphic xlink:href="1678-4170-abc-94-01-0102-00016-gt04-en.jpg"/></table-wrap>
      </p>
      <p>There was a large number of patients with preserved systolic function, with a predominance of the FMP group (<xref ref-type="table" rid="en_16t01-body3">Table 1</xref>). In the population as a whole, 90 patients had HFDEF and 119 had HFNEF. GFR was lower in the group with HFDEF (57.6&#177;66.2 <italic>vs</italic>. 94.8&#177;36.6 ml/min/1.73m<sup>2</sup>; p=0.01). There was no difference regarding the prevalence of anemia in the two groups (23.3% <italic>vs</italic>. 18.5%; p=0.34). The prevalence of moderate to severe kidney dysfunction was higher in the group with HFDEF (32.2% vs. 16.8% p=0.01).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In the present analysis, anemia was present in 22.8% of the patients of the population as a whole, in 25% of the UH group and 21.1% of the FMP group, with no statistically significant difference between the two groups. Prevalence data vary greatly according to the definition used for anemia and according to the studied population. In studies that analyze patients with mild to moderate systolic dysfunction and in asymptomatic patients, the prevalence values are similar to the ones found in the present study<sup>13,20</sup>.</p>
      <p>To understand the problem of anemia in HF, it is important to know the factors that influence the prevalence of anemia and know the consistency of the association between anemia and mortality in several populations of patients with HF. A recently published systematic review aimed at evaluating the prevalence of anemia, separating the publications according to the definition of anemia used in the study, the clinical characteristics of the patients involved, the prevalence of anemia in the studied sample and the association between anemia and mortality. When the prevalence of anemia was analyzed in outpatient clinic patients, 10 studies were selected and the prevalence rates varied between 15% and 61%<sup>29</sup>.</p>
      <p>Such distinct prevalence rates were analyzed and based on the comparison of the clinical characteristics of these outpatient clinic patients (from different centers), it was observed that the prevalence of anemia was higher in populations with higher mean age, more severe HF (estimated by the NYHA classification) and a higher prevalence of comorbidities such as diabetes mellitus (DM) and chronic kidney disease (CKD)<sup>29</sup>. Studies that evaluated the prevalence of anemia in outpatient clinic centers for the treatment of HF found prevalence rates that were similar to those found in the present study, varying between 15% and 30%<sup>29</sup>.</p>
      <p>Anemia seems to be an important comorbidity, not only in patients with HFDEF, but also in those with HFNEF. In a study that assessed the prevalence and the importance of anemia in 137 patients with HFNEF, a high prevalence (40%) was observed, as well as its association with a worse prognosis<sup>30</sup>. Similarly to the present study, that study did not show a statistically significant difference regarding the prevalence of anemia in patients with or without decreased EF, demonstrating that anemia in HF can be quite prevalent, regardless of the ejection fraction.</p>
      <p>Our study confirms that kidney dysfunction is a factor that is independently associated with anemia. The presence of moderate to severe kidney dysfunction (GFR&lt;60 mL/min) is associated with a decrease in the production of erythropoietin (EPO) and a progressive decrease in hemoglobin values<sup>10,13</sup>.</p>
      <p>The decreased kidney function can be associated with adverse events in HF and it can be a marker of severity or a reflex of the coexisting kidney disease<sup>31</sup>. A study that evaluated kidney function in symptomatic and asymptomatic patients with LV systolic dysfunction showed that moderate degrees of kidney dysfunction confer a poor prognosis<sup>31</sup>.</p>
      <p>A recent study analyzed the impact of anemia on the decline of kidney function in patients with HF. A rapid decrease in kidney function was defined as the decrease in GFR<underline>&gt;</underline>6 ml/min/1.73m<sup>2</sup>/year. A total of 6.360 patients were assessed, with a mean age of 59 years and 31% presented chronic kidney failure and 6% presented anemia. The time of follow-up was 2 years and anemia was associated with a rapid decrease in kidney function in patients with HF, particularly patients that already presented kidney function alteration<sup>32</sup>.</p>
      <p>Anemia is often associated with decreased BMI values, a finding that suggests that patients with cachexia present a higher risk of anemia<sup>16</sup>. Serum levels of cytokines and inflammatory markers are elevated in patients with cachexia and can contribute to the development of anemia through a series of mechanisms<sup>16</sup>.</p>
      <p>In the present study, although we found BMI values that were slightly lower in patients with anemia, there was no statistically significant association between this variable and anemia. It is worth mentioning that none of the patients in the present study met the criteria for cachexia or malnutrition.</p>
      <p>Anemia can also be related to the use of some medications such as ACEI and acetylsalicylic acid<sup>22</sup>. In the present study, we did not find an association between anemia and these medications. In the FMP group, however, the use of loop diuretics was more frequent in the anemic than in the non-anemic individuals. This finding probably does not mean a causal association, but a reflex of the worsening in kidney function, when thiazide diuretics are substituted by loop diuretics. Nevertheless, a possible role of diuretics in the worsening of kidney function in patients with HF has been suggested<sup>33</sup>. It is not clear, therefore, whether the diuretics are the cause of the worsening in kidney function or if they work as risk markers, as their use is associated with more severe cases<sup>33</sup>.</p>
      <p>The limitations of the present study include the fact that we did not study all possible mechanisms of anemia. Although the kidney dysfunction showed to be associated with the presence of anemia, we cannot establish a cause-and-effect relation and we cannot state whether or not additional mechanisms contributed to the occurrence of anemia.</p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>The prevalence of anemia in patients with HF treated by family doctors in the community was similar to that found in a specialized outpatient clinic of a university hospital, showing that it is prevalent even in non-selected populations. Kidney function, assessed through urea or creatinine levels, was the only factor that was independently associated with the presence of anemia in the two populations.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of master submitted by Eduarda Barcellos dos Santos, from Universidade Federal Fluminense.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
